share_log

EF Hutton Maintains Buy on Pasithea Therapeutics, Lowers Price Target to $2

Benzinga ·  Apr 3, 2023 10:01

EF Hutton analyst Constantine Davides maintains Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and lowers the price target from $2.3 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment